ABSTRACT
BACKGROUND: Patients with atrial fibrillation (AF) may benefit from undergoing concomitant interventions of left atrial catheter ablation and device occlusion of the left atrial appendage (LAA) as a two-pronged strategy for rhythm control and stroke prevention. We report on the outcome of combined procedures in a single center case series over a 5-year timeframe. METHODS: Ninety-eight patients with non-valvular AF and a mean CHA2DS2-VASc score 2.6±1.0 underwent either first time, or redo pulmonary vein isolation (PVI) procedures, followed by successful implant of a Watchman® device. RESULTS: All procedures were generally uncomplicated with a mean case time of 213±40 min. Complete LAA occlusion was achieved at initial implant in 92 (94%) patients. Satisfactory LAA occlusion was achieved in 100% of patients at 12 months, with a complete LAA occlusion rate of 86%. All patients discontinued oral anticoagulation. Persistent late peri-device leaks were more frequently associated with device angulation or shoulder protrusion, and were associated with a significantly lower achieved device compression of 12±3% vs. 15±5% (p<0.01) than complete occlusion. One ischemic stroke was recorded over a mean follow-up time of 802±439 days. Twelve months׳ freedom from detectable AF was achieved in 77% of patients. CONCLUSIONS: Combined procedures of catheter ablation for AF and Watchman® LAA implant appear to be feasible and safe, with excellent rates of LAA occlusion achieved and an observed stroke rate of 0.5% per year during mid-term follow-up. Incomplete occlusion was associated with lower achieved device compression and was more frequently associated with suboptimal device position.
ABSTRACT
Left ventricular noncompaction (LVNC) is a cardiomyopathy that occurs due to an arrest of myocardial maturation during embryogenesis. The diagnostic echocardiographic features in individuals with LVNC include a thick, bilayered myocardium, prominent ventricular trabeculations, and deep intertrabecular recesses. Clinical features associated with LVNC vary in asymptomatic and symptomatic patients, and include the potential for heart failure, conduction defects (eg, left bundle branch block), supraventricular and ventricular arrhythmias, thromboembolic events, and sudden cardiac death. The authors report five cases that emphasize asymptomatic and apparently benign symptoms in patients with LVNC; despite normal physical examination and 12-lead electrocardiogram results, all of these cases unveiled potentially serious clinical consequences. These cases highlight the concern that LVNC patients with mild to moderate left ventricular systolic dysfunction, particularly in the presence of ventricular arrhythmias or a family history of sudden cardiac death, may need consideration for an implantable cardioverter defibrillator (ICD). All potential benefits of an ICD need to be balanced by the risk of device infection, lead and device malfunction, and potential for inappropriate shocks.
ABSTRACT
Aortic root and ascending aortic dilatation are indicators associated with risk of aortic dissection, which varies according to underlying etiologic associations, indexed aortic root size, and rate of progression. Typical aortic involvement is most commonly seen in syndromic cases for which there is increasing evidence that aortic aneurysm represents a spectrum of familial inheritance associated with variable genetic penetrance and phenotypic expression. Aortic root and ascending aortic dimensions should be measured routinely with echocardiography. Pharmacologic therapy may reduce the rate of progression. Timing of surgical intervention is guided by indexed aortic size and rate of change of aortic root and ascending aorta dimensions. Lifelong surveillance is recommended.
Subject(s)
Aortic Aneurysm/therapy , Actins/deficiency , Actins/genetics , Aortic Aneurysm/diagnosis , Aortic Aneurysm/genetics , Aortic Aneurysm, Thoracic/diagnosis , Aortic Aneurysm, Thoracic/genetics , Aortic Aneurysm, Thoracic/therapy , Aortic Valve/abnormalities , Arachnodactyly/diagnosis , Arachnodactyly/genetics , Arachnodactyly/therapy , Bicuspid Aortic Valve Disease , Contracture/diagnosis , Contracture/genetics , Contracture/therapy , Diagnosis, Differential , Ductus Arteriosus, Patent/diagnosis , Ductus Arteriosus, Patent/genetics , Ductus Arteriosus, Patent/therapy , Echocardiography , Ehlers-Danlos Syndrome/diagnosis , Ehlers-Danlos Syndrome/genetics , Ehlers-Danlos Syndrome/therapy , Heart Valve Diseases/diagnosis , Heart Valve Diseases/genetics , Heart Valve Diseases/therapy , Humans , Iris/abnormalities , Livedo Reticularis/diagnosis , Livedo Reticularis/genetics , Livedo Reticularis/therapy , Loeys-Dietz Syndrome/diagnosis , Loeys-Dietz Syndrome/genetics , Loeys-Dietz Syndrome/therapy , Marfan Syndrome/diagnosis , Marfan Syndrome/genetics , Marfan Syndrome/therapy , Mitral Valve Prolapse/diagnosis , Mitral Valve Prolapse/genetics , Mitral Valve Prolapse/therapy , Myopia/diagnosis , Myopia/genetics , Myopia/therapy , Prognosis , Skin Diseases/diagnosis , Skin Diseases/genetics , Skin Diseases/therapyABSTRACT
Background Patients with atrial fibrillation (AF) may be interested in undergoing concomitant interventions of left atrial catheter ablation and device occlusion of the left atrial appendage (LAA). We report on the feasibility and outcome of combined procedures in a single centre case series. Methods Twenty-six patients underwent either first time or redo pulmonary vein isolation (PVI) procedures followed by successful implant of a Watchman® device. Results All procedures were uncomplicated with a mean case time of 233 ± 38 minutes. Maximal LAA orifice dimension was smaller in 3 of 26 patients post PVI (range 1mm) than on the pre-procedural transoesophageal echocardiogram (TOE). A new peri-device leak of maximum 3mm was noted in 5 of 26 patients at 6 week follow-up TOE, but resolved in 4 by the 6 month follow-up. Conclusion Combined procedures for catheter ablation for AF and Watchman® LAA implant appear to be feasible and safe with satisfactory occlusion of the LAA maintained at follow-up.
ABSTRACT
PURPOSE: Successful implantation of percutaneous left atrial appendage (LAA) occlusion devices requires an accurate understanding of LAA anatomy and orifice dimensions. We sought to quantitatively compare LAA anatomy in patients with paroxysmal and persistent patterns of atrial fibrillation (AF). METHODS: Fifty-nine consecutive patients undergoing catheter ablation for AF underwent pre-procedural multislice cardiac computed tomography (CT) scans. Maximal LAA orifice dimensions and left atrial and LAA volumes were measured from three-dimensional segmented CT reconstructions. Thirty-six patients with paroxysmal and 23 with persistent AF were analysed. RESULTS: The mean maximal LAA orifice dimension was larger in persistent (27.2 ± 4 mm) than paroxysmal AF (22.9 ± 3 mm, p < 0.001). A strong correlation was found between both increasing LAA volume (r = 0.76), maximal LAA orifice dimension (r = 0.63) and left atrial volume. CONCLUSIONS: Increased LAA orifice dimension is associated with left atrial enlargement in AF. This finding may impact LAA occlusion device sizing.
